CL2012001912A1 - Combinacion oftalmica que comprende un agonista del receptor de adenosina a1 y un analogo de prostaglandina; kit que la comprende; util para la reduccion de la presion intraocular en un ojo de un individuo. - Google Patents

Combinacion oftalmica que comprende un agonista del receptor de adenosina a1 y un analogo de prostaglandina; kit que la comprende; util para la reduccion de la presion intraocular en un ojo de un individuo.

Info

Publication number
CL2012001912A1
CL2012001912A1 CL2012001912A CL2012001912A CL2012001912A1 CL 2012001912 A1 CL2012001912 A1 CL 2012001912A1 CL 2012001912 A CL2012001912 A CL 2012001912A CL 2012001912 A CL2012001912 A CL 2012001912A CL 2012001912 A1 CL2012001912 A1 CL 2012001912A1
Authority
CL
Chile
Prior art keywords
kit
eye
useful
individual
receptor agonist
Prior art date
Application number
CL2012001912A
Other languages
English (en)
Spanish (es)
Inventor
Norman N Kim
William K Mcvicar
Thomas Mccauley
Rudolf A Baumgartner
Original Assignee
Inotex Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44258984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012001912(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotex Pharmaceuticals Corp filed Critical Inotex Pharmaceuticals Corp
Publication of CL2012001912A1 publication Critical patent/CL2012001912A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
CL2012001912A 2010-01-11 2012-07-09 Combinacion oftalmica que comprende un agonista del receptor de adenosina a1 y un analogo de prostaglandina; kit que la comprende; util para la reduccion de la presion intraocular en un ojo de un individuo. CL2012001912A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29380610P 2010-01-11 2010-01-11

Publications (1)

Publication Number Publication Date
CL2012001912A1 true CL2012001912A1 (es) 2013-04-19

Family

ID=44258984

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012001912A CL2012001912A1 (es) 2010-01-11 2012-07-09 Combinacion oftalmica que comprende un agonista del receptor de adenosina a1 y un analogo de prostaglandina; kit que la comprende; util para la reduccion de la presion intraocular en un ojo de un individuo.

Country Status (29)

Country Link
US (3) US8877732B2 (forum.php)
EP (1) EP2523669B1 (forum.php)
JP (2) JP2013516495A (forum.php)
KR (1) KR20120115344A (forum.php)
CN (1) CN102711771B (forum.php)
AU (1) AU2011203897B2 (forum.php)
BR (1) BR112012017106A2 (forum.php)
CA (1) CA2784908A1 (forum.php)
CL (1) CL2012001912A1 (forum.php)
CO (1) CO6571924A2 (forum.php)
CY (1) CY1118510T1 (forum.php)
DK (1) DK2523669T3 (forum.php)
EA (1) EA025415B1 (forum.php)
ES (1) ES2613698T3 (forum.php)
HR (1) HRP20170007T1 (forum.php)
HU (1) HUE030566T2 (forum.php)
IL (1) IL220604A (forum.php)
IN (1) IN2012DN06592A (forum.php)
LT (1) LT2523669T (forum.php)
ME (1) ME02608B (forum.php)
MX (1) MX2012007661A (forum.php)
PH (1) PH12012501320A1 (forum.php)
PL (1) PL2523669T3 (forum.php)
PT (1) PT2523669T (forum.php)
RS (1) RS55615B1 (forum.php)
SG (2) SG182285A1 (forum.php)
SI (1) SI2523669T1 (forum.php)
SM (2) SMT201700017T1 (forum.php)
WO (1) WO2011085361A1 (forum.php)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ596428A (en) * 2009-05-01 2014-03-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans
IN2012DN06592A (forum.php) 2010-01-11 2015-10-23 Inotek Pharmaceuticals Corp
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
SI2807178T1 (sl) * 2012-01-26 2017-09-29 Inotek Pharmaceuticals Corporation Anhidridni polimorf (2R,3S,4R,5R)-5-(6-(ciklofentilamino)-9H-purin-9-il)-3,4-dihidroksite- trahidrofuran-2-il))metil nitrat in postopki njegove priprave
KR20150139501A (ko) * 2013-03-15 2015-12-11 이노텍 파마슈티컬스 코포레이션 안과용 제형
CN105188713A (zh) * 2013-03-15 2015-12-23 伊诺泰克制药公司 提供眼部神经保护的方法
RU2712163C2 (ru) 2014-10-24 2020-01-24 Оно Фармасьютикал Ко., Лтд. Активатор kcnq2-5 каналов
US20160158267A1 (en) * 2014-12-03 2016-06-09 Inotek Pharmaceuticals Corporation Methods of preventing, reducing or treating macular degeneration

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4935635B1 (forum.php) 1970-12-28 1974-09-25
CH563405A5 (forum.php) 1971-09-10 1975-06-30 Duschinsky Robert Dr Schweiz I
DE2226295A1 (de) 1972-05-30 1973-12-20 Henning Berlin Gmbh Salpetersaeureester von purinnucleosiden und verfahren zur herstellung derselben
DE2342479A1 (de) 1973-08-23 1975-03-13 Merck Patent Gmbh Ribonucleosid-5'-nitrate und verfahren zu ihrer herstellung
GB2001976B (en) 1977-08-03 1982-03-10 Yamasa Shoyu Kk S-adenosyl-l-methionine compositions and production thereof
US4849311A (en) 1986-09-24 1989-07-18 Toa Nenryo Kogyo Kabushiki Kaisha Immobilized electrolyte membrane
US4968697A (en) 1987-02-04 1990-11-06 Ciba-Geigy Corporation 2-substituted adenosine 5'-carboxamides as antihypertensive agents
US5219840A (en) 1987-04-06 1993-06-15 Sandoz Ltd. Antihypertensive 9-(2,N6 -disubstituted adenyl) ribofuranuronic acid derivatives
US5221763A (en) * 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
US5591887A (en) * 1987-04-30 1997-01-07 R-Tech Ueno, Ltd. Prostaglandins of the F series
US6187813B1 (en) * 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
DE03014533T1 (de) * 1988-09-06 2004-07-15 Pharmacia Ab Prostaglandinderivative zur Behandlung von Glaukom oder okuläre Hypertension
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5140015A (en) 1990-02-20 1992-08-18 Whitby Research, Inc. 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents
US5280015A (en) 1990-09-05 1994-01-18 The United States Of America As Represented By The Department Of Health And Human Services 2-substituted adenosines and 2-substituted adenosine 5'-carboxamides
JP3020580B2 (ja) 1990-09-28 2000-03-15 株式会社日立製作所 マイクロ波プラズマ処理装置
US5206222A (en) 1991-05-22 1993-04-27 Vanderbilt University Methods for the reduction of myocardial reperfusion injury
HU212570B (en) * 1991-06-24 1996-08-29 Chinoin Gyogyszer Es Vegyeszet Process for producing 13,14-dihydro-15(r)-17-phenyl-18,19,20-trinor-pgf2alfa-isopropylester
US5407793A (en) 1991-10-18 1995-04-18 University Of Pittsburgh Of The Commonwealth System Of Higher Education An aqueous heart preservation and cardioplegia solution
US5278150A (en) 1992-04-24 1994-01-11 Whitby Research, Inc. 2-hydrazoadenosines and their utility for the treatmeat of vascular conditions
DK62692D0 (forum.php) 1992-05-14 1992-05-14 Novo Nordisk As
AU4772493A (en) 1992-07-15 1994-02-14 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Sulfo-derivatives of adenosine
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5338430A (en) 1992-12-23 1994-08-16 Minnesota Mining And Manufacturing Company Nanostructured electrode membranes
US5443836A (en) 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
EP0708781B1 (en) 1993-07-13 2001-10-04 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services A 3 adenosine receptor agonists
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
WO1995011681A1 (en) 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
EP0704215A3 (en) 1994-06-02 1998-04-01 Takeda Chemical Industries, Ltd. Inhibitor of vascular permeability enhancer
GB9414193D0 (en) 1994-07-14 1994-08-31 Glaxo Group Ltd Compounds
US5801159A (en) 1996-02-23 1998-09-01 Galileo Laboratories, Inc. Method and composition for inhibiting cellular irreversible changes due to stress
CN1164122A (zh) 1996-03-01 1997-11-05 株式会社日立制作所 等离子处理机及其处理方法
AU2022497A (en) 1996-03-13 1997-10-01 Novo Nordisk A/S A method of treating disorders related to cytokines in mammals
WO1997033879A1 (en) 1996-03-15 1997-09-18 Merck & Co., Inc. Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
US5789416B1 (en) 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
TW528755B (en) 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2289731A1 (en) 1997-05-09 1998-11-12 The United States Of America, Represented By The Secretary, Department O F Health And Human Services Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
JP2001519386A (ja) 1997-10-15 2001-10-23 トーマス・ジェファーソン・ユニバーシティ 哺乳動物における血管収縮または血管痙攣を予防または緩和するための一酸化窒素供与体組成物、方法、装置およびキット
WO1999020284A1 (en) 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
GB9723590D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723566D0 (en) 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
FR2775901B1 (fr) * 1998-03-13 2000-07-21 Logeais Labor Jacques Sels de cetoacides et de derives amines, et leur utilisation pour la preparation de medicaments
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
US6528516B1 (en) 1998-07-16 2003-03-04 Trustees Of The University Of Pennsylvania, The Center For Technology Transfer Methods for reducing intraocular pressure using A3 adenosine receptor antagonists
EP1121372B1 (en) 1998-10-16 2006-06-28 Pfizer Limited Adenine derivatives
IL127947A0 (en) 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6214807B1 (en) 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6180615B1 (en) 1999-06-22 2001-01-30 Cv Therapeutics, Inc. Propargyl phenyl ether A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
EP1194441B1 (en) 1999-06-22 2003-10-22 Cv Therapeutics, Inc. A2a receptor agonists
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
US6368573B1 (en) 1999-11-15 2002-04-09 King Pharmaceuticals Research And Development, Inc. Diagnostic uses of 2-substituted adenosine carboxamides
US6258793B1 (en) 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
GB9930071D0 (en) 1999-12-20 2000-02-09 Glaxo Group Ltd Medicaments
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
US20010051612A1 (en) 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US20030010454A1 (en) 2000-03-27 2003-01-16 Bailey Andrew D. Method and apparatus for varying a magnetic field to control a volume of a plasma
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
EP1307191A2 (en) 2000-07-28 2003-05-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
WO2002055085A2 (en) 2001-01-16 2002-07-18 Can-Fite Biopharma Ltd. Use of an adenosine a3 receptor agonist for inhibition of viral replication
GB2372742A (en) 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
US20040204481A1 (en) 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US20030013675A1 (en) 2001-05-25 2003-01-16 Boehringer Ingelheim Pharma Kg Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
CA2456806C (en) 2001-08-08 2011-10-18 Brown University Research Foundation Methods for micronization of hydrophobic drugs
WO2003029264A2 (en) 2001-10-01 2003-04-10 University Of Virginia Patent Foundation 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof
DE60325572D1 (de) 2002-04-18 2009-02-12 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
MXPA04009471A (es) 2002-04-30 2005-01-25 Alcon Inc Agentes que regulan, inhiben o modulan la actividad y/o expresion de factor de crecimiento de tejido de conexion (ctgf) como un medio unico para ambos reducir la presion intraocular y tratar retinopatias glaucomatosas/neuropatias opticas.
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
GB2436255B (en) 2002-12-23 2007-11-28 Global Cardiac Solutions Pty L Organ preconditioning, arrest, protection, preservation and recovery
US20060034941A1 (en) 2002-12-23 2006-02-16 Global Cardiac Solutions Pty Ltd Organ preconditioning, arrest, protection, preservation and recovery
CA2468664C (en) 2003-06-03 2012-03-06 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
AU2005207037A1 (en) 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
DK1758596T3 (da) * 2004-05-26 2010-07-26 Inotek Pharmaceuticals Corp Purinderivater som adenosin-A1-receptoragonister og fremgangsmåder til anvendelse deraf
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
CA2573682A1 (en) 2004-07-12 2006-02-16 Cv Therapeutics, Inc. Process for the preparation of a1 adenosine receptor agonists
JP5688199B2 (ja) * 2004-10-18 2015-03-25 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 平滑筋を弛緩させる活性成分を含むリポソーム組成物、その組成物の製造方法、及び治療剤としての用途
US20090220516A1 (en) 2005-06-22 2009-09-03 Alan Laties Neuroprotection of retinal ganglion cells
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
BRPI0707446A2 (pt) 2006-02-02 2011-05-03 Allergan Inc composições e métodos para o tratamento de doença oftálmica
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US20070238694A1 (en) 2006-03-23 2007-10-11 Inotek Pharmaceuticals Corporation Purine compounds and methods of use thereof
US8163737B2 (en) 2006-06-13 2012-04-24 Vertex Pharmaceuticals Incorporated CGRP receptor antagonists
BRPI0714587A2 (pt) 2006-07-25 2013-05-07 Osmotica Corp suluÇço oftÁlmica aquosa e uso da nesna
MX2009003750A (es) 2006-10-06 2009-06-18 Univ Pennsylvania Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
NZ576524A (en) 2006-11-10 2012-01-12 Basf Se Crystalline modification of fipronil
EP2099468B1 (en) 2006-12-05 2018-07-11 The Royal Institution for the Advancement of Learning/McGill University Methods of use of trk receptor modulators
JP2008266143A (ja) 2007-04-16 2008-11-06 Santen Pharmaceut Co Ltd アデノシン誘導体を有効成分として含有する緑内障治療剤
EP2205071B1 (en) 2007-10-11 2015-07-22 Biogen MA Inc. Lingo-1 antagonists and trkb agonists for use in the treatment of glaucoma
WO2009076580A2 (en) 2007-12-12 2009-06-18 Thomas Jefferson University Compositions and methods for the treatment and prevention of cardiovascular diseases
JP2011511802A (ja) 2008-02-07 2011-04-14 ギリアード・パロ・アルト・インコーポレイテッド Ａｂｃａ−１を上昇させる化合物およびかかる化合物の使用方法
EP3693014A1 (en) 2008-11-13 2020-08-12 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
NZ596428A (en) * 2009-05-01 2014-03-28 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans
EP2493480A4 (en) 2009-10-26 2013-04-10 Inotek Pharmaceuticals Corp OPHTHALMIC FORMULATION AND MANUFACTURING METHOD THEREFOR
WO2011077435A1 (en) 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure
IN2012DN06592A (forum.php) 2010-01-11 2015-10-23 Inotek Pharmaceuticals Corp
US20110217262A1 (en) 2010-03-05 2011-09-08 Kornfield Julia A Treatment of Ocular Surface Disorders by Increasing Conjunctival Vascular Permeability
SI2555776T1 (sl) * 2010-03-19 2017-05-31 Inotek Pharmaceuticals Corporation Kombinirani sestavki adenozin A1 agonistov in ne-selektivni blokatorji beta-adrenergičnega receptorja za zmanjšanje intraokularnega tlaka
RS55617B1 (sr) 2010-03-19 2017-06-30 Inotek Pharmaceuticals Corp Kombinovane kompozicije adenozinskih a1 agonista i inhibitora ugljene anhidraze za snižavanje intraokularnog pritiska
WO2011119919A1 (en) 2010-03-26 2011-09-29 Inotek Pharmaceuticals Corporation Adenosine compounds and their use thereof
SG184221A1 (en) * 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof

Also Published As

Publication number Publication date
SI2523669T1 (sl) 2017-05-31
HUE030566T2 (en) 2017-05-29
EP2523669B1 (en) 2016-12-07
ES2613698T3 (es) 2017-05-25
US20150038448A1 (en) 2015-02-05
US20110172177A1 (en) 2011-07-14
WO2011085361A1 (en) 2011-07-14
EP2523669A1 (en) 2012-11-21
MX2012007661A (es) 2012-08-01
CO6571924A2 (es) 2012-11-30
SG182285A1 (en) 2012-08-30
IN2012DN06592A (forum.php) 2015-10-23
JP2016040320A (ja) 2016-03-24
SG10201502588UA (en) 2015-05-28
RS55615B1 (sr) 2017-06-30
EA201201011A1 (ru) 2012-12-28
PH12012501320A1 (en) 2013-01-21
LT2523669T (lt) 2017-04-25
CA2784908A1 (en) 2011-07-14
CY1118510T1 (el) 2017-07-12
EP2523669A4 (en) 2013-08-28
EA025415B1 (ru) 2016-12-30
CN102711771A (zh) 2012-10-03
IL220604A (en) 2017-01-31
PT2523669T (pt) 2017-01-31
US9370530B2 (en) 2016-06-21
ME02608B (me) 2017-06-20
SMT201700017B (it) 2017-03-08
US8877732B2 (en) 2014-11-04
JP2013516495A (ja) 2013-05-13
PL2523669T3 (pl) 2017-06-30
HRP20170007T1 (hr) 2017-03-10
IL220604A0 (en) 2012-08-30
KR20120115344A (ko) 2012-10-17
AU2011203897B2 (en) 2016-11-17
BR112012017106A2 (pt) 2018-05-29
CN102711771B (zh) 2016-05-18
AU2011203897A1 (en) 2012-08-09
US20160367586A1 (en) 2016-12-22
SMT201700017T1 (it) 2017-03-08
DK2523669T3 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
CL2012001912A1 (es) Combinacion oftalmica que comprende un agonista del receptor de adenosina a1 y un analogo de prostaglandina; kit que la comprende; util para la reduccion de la presion intraocular en un ojo de un individuo.
TWD190952S (zh) 車輛前下保險桿蓋(一)
AR112286A2 (es) Sistema polimérico de lágrimas artificiales
BRPI0910368B8 (pt) uso de um ou mais biointensificadores, composição para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores e colírio para o uso de um ou mais intensificadores escolhidos entre biointensificadores e fotointensificadores
BR112014030330A2 (pt) lentes oftálmicas levando em consideração a lateralidade do usuário
BR112017022525A2 (pt) ?composição de polipropileno reforçada com fibras, artigos, e, processo para preparação de uma composição reforçada com fibras?
AU2018260857A1 (en) Artificial tears comprising sodium hyaluronate and carboxymethylcellulose
CR20110163A (es) Uso de ditiina-tetracarboxamidas para combatir hongos fitopatógenos
MY164536A (en) Syringe
MX2013011357A (es) Anticuerpos dirigidos contra icos y usos de los mismos.
PH12013502482A1 (en) Hydrophobic acrylic introcular lens materials
PH12013502395A1 (en) Hydrophobic acrylic intraocular lens materials
MX346220B (es) Materiales de dispositivo oftalmico, hidrofobico de baja adherencia.
PH12017500922A1 (en) Stabilized omega-3 ophthalmic compositions
MX2015003009A (es) Dispositivo implantable para moldear la curvatura de la cornea.
UY3985Q (es) Paquete de cigarillos simulado
CL2012002612A1 (es) Compuestos derivados de benciloxicicloalquiladenosina, como agonistas selectivos de receptores de adenosina a1; composicion farmaceutica oftalmica; y su uso para el tratamiento de una afeccion seleccionada entre presion intraocular elevada, hipertension ocular o glaucoma.
MX2017013918A (es) Composicion que contiene norbixina para proteger las celulas del epitelio de pigmento de la retina.
TWD194846S (zh) 車輛前下保險桿蓋(一)
CR20130094A (es) Agonistas de adenosina a1 para el tratamiento del glaucoma y la hipertensión ocular
CR20120360A (es) Combinación triple disminuir la presión intraocular
BRPI0920662A2 (pt) oncostatina m como um reforço da atividade imunoestimulatória de células epiteliais humanas
BR112013007369A2 (pt) lente com parede de menisco linear de múltiplos segmentos
BR112012010795A2 (pt) Formulações oftálmicas contendo gama lactams substituídas e métodos para uso das mesmas
UA75102U (en) "AQUALIFT" biocompatible hydrogel